Skip to main content
. Author manuscript; available in PMC: 2021 Jan 1.
Published in final edited form as: J Cardiovasc Comput Tomogr. 2019 Jun 25;14(1):44–54. doi: 10.1016/j.jcct.2019.06.008

Fig. 3.

Fig. 3.

Treatment effect of agressive medical theraphy for obstructive CAD. Left side: Treatment effect of agressive medical theraphy for obstructive CAD (> 50%): light grey column: baseline case assuming that life time statin therapy reduces CAD mortality by 23% (22); mild and dark grey column: sensitivity analysis using the upper (30%) and lower (18%) bounds of the confidence in-terval of relative risk reduction. Right side: Sensitivity analyses for validations in treatment compliance: light grey column: baseline case assuming that life time statin therapy reduces CAD mortality by 23% (22); mild grey column: 5 years of full compliance followed by 5 years of decining compliance (in monthly steps with none of the patients on statins after 10 years); dark grey: full com-pliance for 5 years and no treatment effect afterwards. CAD = Coronary artery disease, RR = Risk reduction.